Dysglycemia

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes

Retrieved on: 
Monday, May 22, 2023
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, BPI, Biochemistry, Obesity, Research and development, Development, Patient, Risk, European, AMF, Analysis, Phase, Volunteering, ERDF, European Regional Development Fund, Research, CHF, Partnership, Metabolism, BARD, Pharmacy, Trial of the century, Dysglycemia, Prediabetes, United Arab Emirates, Public Health Nutrition, Pharmaceutical industry, Medical device, Dietary supplement, Medical imaging, Cryptocurrency, ITT

We have provided unequivocal clinical evidence that TOTUM•63 is a promising solution for millions of people worldwide, helping to prevent the progression to type 2 diabetes.

Key Points: 
  • We have provided unequivocal clinical evidence that TOTUM•63 is a promising solution for millions of people worldwide, helping to prevent the progression to type 2 diabetes.
  • Beyond this great achievement, which opens up a new path, it is also a personal satisfaction, after almost 10 years of hard work."
  • This non-drug, plant-based active substance has the potential to significantly impact the management of early impairments of glucose metabolism."
  • The randomized and placebo-controlled REVERSE-IT Phase II/III study included 636 people with impaired glucose metabolism, ranging from prediabetes to untreated type 2 diabetes (early stage).

Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science

Retrieved on: 
Monday, March 13, 2023
Technology, Diabetes, Fitness & Nutrition, Biotechnology, Biometrics, Other Health, Food, Beverage, Health, Retail, Partner, Waist, European Regional Development Fund, Public Health Nutrition, DSM-IV codes, Database, PEA, Risk, ERDF, European, BPI, AMF, Research, Prediabetes, Patient, Hope, Human, Development, Collection, Phase, Good, Partnership, Research and development, Industrial Affairs Committee (Iceland), Dysglycemia, Pharmaceutical industry, Cryptocurrency

TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes.

Key Points: 
  • TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes.
  • Nestlé Health Science has the exclusive and global commercial rights to use TOTUM•63 in the prediabetes and type 2 diabetes market.
  • We also thank the Nestlé Health Science teams for their guidance and support as part of our strategic partnership on TOTUM•63.
  • In February 2020, Valbiotis signed a long-term global strategic partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM•63.

 Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Pharmaceutical, Health, Institute, Mission statement, Prediabetes, Degenerative disease, Volunteering, Health, IFRS, Time, United Nations Global Compact, De novo, ESG, Hypercholesterolemia, Development, LDL, Statutory auditor, Director, Risk, Corporate social responsibility, Phase, Research, NASH, Small, Nutrition, Russell Midcap Index, Company, Population, Pernod Ricard, Review, Non-alcoholic fatty liver disease, Partnership, CSR, Food science, Environment, Program, Star Trek: Phase II, Physician, Université Laval, Triglyceride, Research and development, Liver, Board, Christofle, INAF, Marketing, Awareness, ISO, Dysglycemia, INSIGHT, Pharmaceutical industry, Dietary supplement

In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).

Key Points: 
  • In July 2022, Valbiotis announced the end of recruitment with the randomization of the last of the 600 participating volunteers ( press release of July 28, 2022 ).
  • In February 2022, Valbiotis received approval to initiate two Phase II/III clinical trials, INSIGHT and INSIGHT 2 ( press release of February 17, 2022 ).
  • The Company's interim financial statements, prepared in accordance with IFRS, were approved by the Board of Directors on September 7, 2022.
  • They have been subject to a limited review by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com (investors section).

Glytec and CPS Collaborate to Provide Evidence-Based Glycemic Management Support for Pharmacy Departments Nationwide

Retrieved on: 
Tuesday, August 23, 2022
Technology, Managed Care, Medical Devices, General Health, Infectious Diseases, Hospitals, Science, Nursing, Medical Supplies, FDA, Diabetes, Health, Research, Software, Other Health, Pharmaceutical, Practice Management, CPS, Patient safety, Doctor of Pharmacy, Pharmacist, Dysglycemia, Technology, Centers for Medicare & Medicaid Services, Caregiver, E-GMS, Solution, IV, Lists of diseases, Death, Doctor, CMS, Infection, EHR, Fuel injection, LinkedIn, Senior, Diagnosis, Data management, Hospital, Center, Health, Insulin, Medicare, FDA, Pharmacy, Population, LLC, Nursing, Diabetes, Hypoglycemia, Patient, Medical device, Pharmaceutical industry

Through this collaboration, CPS client facilities may contract for Glytecs eGlycemic Management System (eGMS) and Glytecs technical resources to be available to their healthcare professionals, empowering them to establish best-in-class glycemic management programs.

Key Points: 
  • Through this collaboration, CPS client facilities may contract for Glytecs eGlycemic Management System (eGMS) and Glytecs technical resources to be available to their healthcare professionals, empowering them to establish best-in-class glycemic management programs.
  • Hospital pharmacy leaders are facing heightened challenges in todays environment, and glycemic management has rapidly ascended to the top of that list.
  • Decades of clinical research have shown that optimal glycemic management in the hospital positively impacts patient outcomes and business performance.
  • CPS solutions include inpatient pharmacy solutions and specialty and ambulatory pharmacy solutions, pharmacy consulting, 340B services, telepharmacy services, supply chain and materials management services, rehabilitation services, and more.

Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science

Retrieved on: 
Thursday, July 28, 2022
Health, Science, Research, Clinical Trials, Cardiology, Dysglycemia, European Regional Development Fund, Research, Ministry of Health, Nutrition and Indigenous Medicine, Union, Development, Partnership, Lists of diseases, Risk, AMF, Volunteering, Type 2 diabetes, Industrial Affairs Committee (Iceland), Company, Degenerative disease, Human, ERDF, Research and development, Phase, Waist, Investor, BPI, Population, Prediabetes, Pharmaceutical industry, Medical device

REVERSE-IT should confirm the positive results of the Phase II clinical study already obtained in a similar population with TOTUM63.

Key Points: 
  • REVERSE-IT should confirm the positive results of the Phase II clinical study already obtained in a similar population with TOTUM63.
  • We would like to thank all the teams involved in this project, as well as our partner Nestl Health Science.
  • TOTUM63 has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study.
  • In February 2020, Valbiotis signed a long-term global strategic partnership with Nestl Health Science for the development and worldwide commercialization of TOTUM63.

RSNA: Artificial Intelligence May Improve Diabetes Diagnosis

Retrieved on: 
Tuesday, April 5, 2022
Linda, Pancreas, The Cancer Imaging Archive (TCIA), Plaque, Blood, DRS, Biomarker, Diagnosis, Radiological Society of North America, University of Wisconsin School of Medicine and Public Health, Society, Prediabetes, Colorectal cancer, Association, National Institutes of Health Clinical Center, Liver, OAK, Research, Radiology, BMI, Public health, Type 2 diabetes, Health, Diabetes, CT scan, National, Time, Doctor of Philosophy, Data, Muscle, Deep learning, Abdomen, RSNA, Education, University, Patient, Disease, Dysglycemia, Radiation, Medical device, Pharmaceutical industry, Medical imaging, Medicine

OAK BROOK, Ill., April 5, 2022   /PRNewswire-PRWeb/ -- Using a fully-automated artificial intelligence (AI) deep learning model, researchers were able to identify early signs of type 2 diabetes on abdominal CT scans, according to a new study published today, April 5, in the journal Radiology.

Key Points: 
  • Using a fully-automated artificial intelligence (AI) deep learning model, researchers were able to identify early signs of type 2 diabetes on abdominal CT scans, according to a new study published in the journal Radiology.
  • Type 2 diabetes affects approximately 13% of all U.S. adults and an additional 34.5% of adults meet the criteria for prediabetes.
  • Previous studies have shown that patients with diabetes tend to accumulate more visceral fat and fat within the pancreas than non-diabetic patients.
  • The results showed that patients with diabetes had lower pancreas density and higher visceral fat amounts than patients without diabetes.